Crossmark

Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen

Crossref DOI link: https://doi.org/10.1136/bmjno-2021-000164

Published Online: 2021-08-12

Published Print: 2021-08

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Arnold, W David https://orcid.org/0000-0001-9889-7036
Severyn, Steven

Zhao, Songzhu

Kline, David

Linsenmayer, Matthew

Kelly, Kristina

Tellez, Marco

Bartlett, Amy

Heintzman, Sarah

Reynolds, Jerry

Sterling, Gary

Weaver, Tristan

Rajneesh, Kiran

Burghes, Arthur H M

Kolb, Stephen J

Elsheikh, Bakri
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04139343 at ClinicalTrials.gov

Documents that mention this clinical trial

Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen
https://doi.org/10.1136/bmjno-2021-000164

nct04591678 at ClinicalTrials.gov

Documents that mention this clinical trial

Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen
https://doi.org/10.1136/bmjno-2021-000164
Funding

Funding for this research was provided by:

Cure SMA (ELS1819)
License Information

License valid from 2021-08-11